Akamai Technologies, Inc. (AKAM) Stock Price Today
Aura AI Summary
Key Stats
- $16.45BMARKET_CAP
- -VOLUME
- TechnologySECTOR
- $161.14FIFTY_TWO_WEEK_HIGH
- $70.53FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $21.39BENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Akamai Technologies, Inc. (AKAM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Akamai Technologies, Inc. has traded between a low of $70.53 and a high of $161.14, highlighting its annual price range. Buy and sell Akamai Technologies, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Most Recent News
Global infant heart monitor market to reach $7.93B by 2035 with 10.85% CAGR, driven by tech advances and home care demand
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...
Halper Sadeh LLC probes fairness of major company sales for shareholders' benefit.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...